Descriptor English: | Oxymetholone | ||||||
Descriptor Spanish: |
Oximetolona
| ||||||
Descriptor Portuguese: | Oximetolona | ||||||
Descriptor French: | Oxymétholone | ||||||
Entry term(s): |
Anadrol Anapolon 50 Hydroxymetholone Oxymethalone Oxymetholone, (17 beta)-Isomer Oxymetholone, (5 alpha,17 alpha)-Isomer |
||||||
Tree number(s): |
D04.210.500.054.040.632 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D010110 | ||||||
Scope note: | A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed) |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Androgens Anabolic Agents |
||||||
Registry Number: | L76T0ZCA8K | ||||||
CAS Type 1 Name: | Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5alpha,17beta)- | ||||||
Public MeSH Note: | 65 |
||||||
History Note: | 65 |
||||||
DeCS ID: | 10290 | ||||||
Unique ID: | D010110 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1965/01/01 | ||||||
Date of Entry: | 1999/01/01 | ||||||
Revision Date: | 2016/05/31 |
-
-
CHEMICALS AND DRUGS
Polycyclic Compounds [D04]Polycyclic Compounds
|
Oxymetholone
- Preferred
Oxymetholone, (5 alpha,17 alpha)-Isomer
- Narrower
Oxymetholone, (17 beta)-Isomer
- Narrower
Anadrol
- Narrower
Anapolon 50
- Narrower
Concept UI |
M0015682 |
Scope note | A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed) |
Preferred term | Oxymetholone |
Entry term(s) |
Hydroxymetholone Oxymethalone |
Concept UI |
M0331236 |
Preferred term | Oxymetholone, (5 alpha,17 alpha)-Isomer |
Concept UI |
M0331237 |
Preferred term | Oxymetholone, (17 beta)-Isomer |
Concept UI |
M0350981 |
Preferred term | Anadrol |
Concept UI |
M0350982 |
Preferred term | Anapolon 50 |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey